Antiviral Therapy of Chronic Hepatitis B

Frequency of YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines

 Abstract Background: Investigators were suspicious of tyrosine-methionine-aspartate-aspartate (YMDD) mutations occurred only in patients who were treated by lamivudine. However, YMDD mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines was reported in some studies. The aim of this study was to evaluate YMDD mutations in Ira...

Vitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)

α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...

بررسی عوامل مرتبط با شدت فیبروز کبد در بیماران مبتلا به هپاتیت‌های مزمن B و C

   Background & Aim: Viral hepatitis has existed since the creation of human. The estimated prevalence of hepatitis is about 3-5%. For patients with chronic hepatitis C and moderate to severe liver fibrosis, antiviral therapy is strongly suggested, while the cases without fibrosis or with mild liver fibrosis are often followed up without receiving antiviral therapy. The purpose of the present s...

Antiviral therapy for hepatitis B in special populations.

There has been much progress in antiviral therapy for chronic hepatitis B; however, antiviral therapy for hepatitis B in special populations is still very challenging. Here, we review antiviral therapy for hepatitis B in special populations, including children and pregnant patients, patients with hepatitis-B-related cirrhosis, patients with acute hepatitis B and chronic hepatitis B surface anti...

Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?

[Antiviral therapy in chronic hepatitis B].

Treatment of chronic hepatitis B remains a clinical challenge. Long-term viral suppression is a major goal of antiviral therapy to improve the clinical outcome of the patients. Antiviral treatment of chronic hepatitis B relies currently on immune modulators such as interferon alpha and its pegylated form, and viral polymerase inhibitors. Because of the slow kinetics of viral clearance and the s...